A Randomized, Open-label, Controlled, Multi-Center Phase II/III Study to Assess the Efficacy and Safety of AZD3759 Vs. a Standard of Care EGFR TKI, As First Line Treatment to EGFR Mutation Positive Advanced NSCLC with CNS Metastases

The first-line treatment with single agent AZD3759 results in superior Progression Free Survival (PFS) compared to Standard of Care (SoC) Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR-TKI), in patients with advanced EGFR mutation positive non-small cell lung cancer (NSCLC) with Central Nervous System (CNS) metastasis

Start Date29 Oct 2018

Sponsor / Collaborator

Alpha Biopharma (Jiangsu) Co., Ltd.

CTR20180609

/ CompletedPhase 2/3

评估 AZD3759 作为一线治疗与EGFR-TKI标准治疗相比，在EGFR突变阳性的晚期NSCLC伴CNS转移患者中的有效性和安全性的II/III期临床研究

[Translation] A phase II/III clinical study to evaluate the efficacy and safety of AZD3759 as first-line treatment compared with standard EGFR-TKI treatment in patients with EGFR mutation-positive advanced NSCLC and CNS metastases

主要目的是通过盲态的独立中心影像审查（BICR），判断作为一线疗法，单独使用AZD3759与EGFR-TKI标准治疗相比，是否能够显著提高研究患者人群的无进展生存期（PFS）。

[Translation]

The main purpose is to determine whether AZD3759 alone as first-line therapy can significantly improve the progression-free survival (PFS) of the study patient population compared with standard treatment with EGFR-TKI through blinded independent central imaging review (BICR).

Start Date18 Oct 2018

Sponsor / Collaborator

AstraZeneca Investment (China) Co. Ltd.

NCT03574402

/ RecruitingPhase 2IIT

An Open-label, Multi-center, Phase II Umbrella Study to Assess Efficacy of Targeted Therapy or Immunotherapy Directed by Next Generation Sequencing (NGS) in Chinese Patients With Advanced NSCLC (TRUMP)

This phase II, umbrella trial study directed by next generation sequencing (NGS) works in Chinese patients with advanced stage NSCLC who never received any anti-tumor treatment. The purpose of this study is to evaluate efficacy of targeted therapies or immunotherapy to NSCLC patients whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug.

Start Date09 Jul 2018

Sponsor / Collaborator

Chinese Thoracic Oncology Group

100 Clinical Results associated with Zorifertinib

100 Translational Medicine associated with Zorifertinib

100 Patents (Medical) associated with Zorifertinib

Literatures (Medical) associated with Zorifertinib

01 Apr 2025·CLINICAL ONCOLOGY

Comparing the Effectiveness and Safety of First-line Interventions in Patients With Advanced Epidermal Growth Factor Receptor-mutant Non-small Cell Lung Cancer, With Particular Focus on Brain Metastatic Status: A Systematic Review and Network Meta-analysis

Article

Author: Wang, T ; Mei, T ; Zhou, Q ; Xu, T

AIMS:

This network meta-analysis (NMA) aimed to identify the most effective first-line intervention (FLI) for advanced epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC), particularly in patients with varying brain metastasis (BM) status.

MATERIALS AND METHODS:

Data were collected from randomized controlled trials (RCTs) evaluating first-line EGFR-tyrosine kinase inhibitors (EGFR-TKIs), either alone or in combination, for EGFR-mutated advanced NSCLC (EMAN) patients. The sources included EMBASE, Web of Science, Cochrane Library, PubMed, and relevant conference abstracts from inception until December 2023.

RESULTS:

A total of 37 RCTs, encompassing 24 intervention options, were included in the NMA. Osimertinib combined with chemotherapy (CT) significantly improved progression-free survival (PFS) compared to aumolertinib (HR, 0.61; 95% CI, 0.40-0.93), furmonertinib (HR, 0.64; 95% CI, 0.41-0.98), lazertinib (HR, 0.64; 95% CI, 0.41-0.98), osimertinib alone (HR, 0.62; 95% CI, 0.48-0.80), osimertinib + bevacizumab (HR, 0.72; 95% CI, 0.51-1.00), befotertinib (HR, 0.57; 95% CI, 0.36-0.90), and zorifertinib (HR, 0.61; 95% CI, 0.39-0.93). Further, amivantamab + lazertinib showed slightly better PFS compared to aumolertinib, furmonertinib, zorifertinib, and osimertinib + bevacizumab (HR <1, but P >0.05). Regarding overall survival (OS), amivantamab + lazertinib demonstrated superior results relative to furmonertinib (HR, 0.54; 95% CI, 0.30-0.95) and befotertinib (HR, 0.43; 95% CI, 0.24-0.77). No significant OS differences were observed among osimertinib, osimertinib + bevacizumab, osimertinib + CT, lazertinib, and amivantamab + lazertinib. In BM patients, osimertinib + CT significantly enhanced PFS compared to osimertinib (HR, 0.47; 95% CI, 0.33-0.66), furmonertinib (HR, 0.44; 95% CI, 0.21-0.90), befotertinib (HR, 0.45; 95% CI, 0.21-1.00), and zorifertinib (HR, 0.47; 95% CI, 0.25-0.89). However, no noticeable PFS differences were observed between osimertinib + CT and amivantamab + lazertinib or aumolertinib. Lastly, osimertinib + CT and zorifertinib were associated with higher rates of all-grade adverse events (AEs) and grade ≥3 AEs, respectively.

CONCLUSIONS:

In EMAN patients, osimertinib + CT and amivantamab + lazertinib were associated with optimal PFS and OS, respectively. Among BM patients, osimertinib + CT offered the best PFS benefits. These findings may assist in clinical decision-making and personalized care for EMAN and BM patients. The study is registered on PROSPERO (CRD42024506995).

01 Jan 2025·ANTI-CANCER DRUGS

Machine learning-based integration develops a multiple programmed cell death signature for predicting the clinical outcome and drug sensitivity in colorectal cancer

Article

Author: Tan, Haiyin ; Ou, Minglin ; Hou, Xianliang ; Li, Chunhong ; Hu, Jiahua ; Mao, Yuhua ; Su, Chunchun ; Liu, Yi

Tumorigenesis and treatment are closely associated with various programmed cell death (PCD) patterns. However, the coregulatory role of multiple PCD patterns in colorectal cancer (CRC) remains unknown. In this study, we developed a multiple PCD index (MPCDI) based on 19 PCD patterns using two machine learning algorithms for risk stratification, prognostic prediction, construction of nomograms, immune cell infiltration analysis, and chemotherapeutic drug sensitivity analysis. As a result, in the TCGA-COAD, GSE17536, and GSE29621 cohorts, the MPCDI can effectively distinguished survival outcomes in CRC patients and served as an independent factor for CRC patients. We then explored the immune infiltration landscape in two groups using the nine algorithms and found more overall immune infiltration in the high-MPCDI group. TIDE scores suggested that the increased immune evasion potential and immune checkpoint inhibition therapy may be less effective in the high-MPCDI group. Immunophenoscores indicated that anti-PD1, anti-cytotoxic T-lymphocyte associated antigen 4 (anti-CTLA4), and anti-PD1-CTLA4 combination therapies are less effective in the high-MPCDI group. In addition, the high-MPCDI group was more sensitive to AZD1332, Foretinib, and IGF1R_3801, and insensitive to AZD3759, AZD5438, AZD6482, Erlotinib, GSK591, IAP_5620, and Picolinici-acid, which suggests that the MPCDI can guide drug selection for CRC patients. As a new clinical classifier, the MPCDI can more accurately distinguish CRC patients who benefit from immunotherapy and develop personalized treatment strategies for CRC patients.

01 Jan 2025·Med

The climb toward intracranial efficacy: Zorifertinib in EGFR-mutant NSCLC with CNS metastases in the EVEREST trial

Article

Author: Rogawski, David ; Roy-O'Reilly, Meaghan

The phase III EVEREST trial evaluating zorifertinib in the treatment of metastatic EGFR-mutant NSCLC was groundbreaking in its specific inclusion of patients with brain metastases.¹ Zorifertinib prolonged systemic and intracranial progression-free survival compared with first-generation EGFR inhibitors, yet questions remain about its efficacy and toxicity compared with osimertinib.

News (Medical) associated with Zorifertinib

30 Jan 2023

·www.prnewswire.com

Alpha Biopharma Submits New Drug Application for Zorifertinib, a Next-Generation EGFR-TKI to Treat EGFR-mutated NSCLC Patients with CNS Metastases

SHANGHAI, Jan. 29, 2023 /PRNewswire/ -- Alpha Biopharma, a developer of innovative drugs, announces that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has accepted its New Drug Application (NDA) for Zorifertinib, a next-generation EGFR-TKI specially designed to treat advanced EGFR-mutated non-small cell lung cancer (NSCLC) patients with central nervous system (CNS) metastases. Zorifertinib is the first EGFR-TKI to be tested in a prospective, controlled registration clinical study for this difficult-to-treat patient population, and if approved, it will bring a much-needed new treatment option for these patients. Data released by the International Agency for Research on Cancer (IARC) of the World Health Organization (SHO) showed that there were 9.96 million cancer deaths worldwide in 2020, and 1.8 million deaths were from lung cancers, making it the most common cause of cancer deaths. Due to the low CNS penetration rate of most current lung cancer drugs, lung cancers metastasized to the CNS were poorly controlled and have become one of the leading causes of NSCLC patient deaths. Zorifertinib is a next-generation EGFR-TKI targeting sensitive EGFR mutations (exon 19 deletion and exon 21 L858R) designed for complete blood-brain barrier (BBB) permeability. In addition, Zorifertinib is not a substrate for the efflux transporters P-gp and BCRP, which allows it to achieve and maintain effective drug exposure in the brain tissues and the cerebrospinal fluid. The EVEREST study was a multinational, multicenter, randomized, open-label, controlled phase II/III clinical trial designed to evaluate the efficacy and safety of Zorifertinib as a first-line treatment for advanced EGFR-mutated NSCLC patients with CNS metastases. The study was carried out in 55 study sites located in the Chinese mainland, Taiwan, South Korea, and Singapore, with a total enrollment of 492 patients. The last patient last visit (LPLV) of the EVEREST study was completed in the third quarter of 2022. Results from the EVEREST study demonstrated that Zorifertinib effectively reduced the risk of disease progression and patient deaths in the target patient population and showed significant efficacy in treating metastatic lesions in the CNS. In addition, Zorifertinib's safety profile is comparable to other approved EGFR-TKI's. The primary resistance mutation at the time of disease progression is the EGFR T790M mutation. Professor Yilong Wu, President of the Chinese Thoracic Oncology Group (CTONG) and the leading principal investigator (PI) of the EVEREST study, said, "Clinical results from this high-quality, controlled study demonstrated that Zorifertinib provided consistent and statistically significant benefits to EGFR-mutated NSCLC patients with different levels of CNS metastasis. It could provide a much-needed new treatment option for these difficult-to-treat patients. The development of Zorifertinib represents a great example of a patient-centric, targeted precision approach to address unmet medical needs. Eric Zhang, CEO of Alpha Biopharma, said, "after many years of dedicated research and development, we are very pleased to witness that all pre-clinical and clinical data have demonstrated that Zorifertinib can achieve and maintain high CNS exposures, that it is safe, and it is advantageous in controlling CNS and overall disease progression in this difficult-to-treat population. We look forward to working closely with the regulatory agencies around the world to bring this innovative treatment option to patients in dire need. About Zorifertinib Zorifertinib is a potent, oral, reversible inhibitor of mutated EGFR (Exon19Del and Exon21L858R). EGFR is widely expressed in human epidermal and stromal cells and is highly expressed in various human malignancies, such as NSCLC. EGFR gene mutation will cause excessive epidermal growth factor receptors on the cell membrane surface, accelerate the abnormal growth and division of cells, and eventually lead to tumorigenesis. CNS metastases are common in EGFR-mutated NSCLC patients and are accompanied by a poor prognosis of earlier disease progression, shorter survival, and lower quality of life. The BBB significantly increases the difficulty of drug penetration into the CNS, which allows the CNS to be a refuge for lung cancer cells. Zorifertinib is a next-generation EGFR-TKI with full blood-brain barrier penetration targeting advanced NSCLC patients with CNS metastases and EGFR-sensitizing mutations. Zorifertinib is currently under NDA submission and has global patent protection. About Alpha Biopharma Alpha Biopharma is a late-stage biopharmaceutical company focusing on developing new therapies for cancers and other unmet medical needs. The Company has submitted its first NDA submission for its small molecule drug Zorifertinib to treat advanced NSCLC patients with CNS metastases and EGFR sensitizing mutations. In addition, in partnership with leading cell therapy company Wugen, Alpha Biopharma is developing memory NK-cells to treat multiple blood and solid tumors and CAR-T cells to treat T-cell lymphomas. It has initiated an IIT clinical study testing memory NK cells in relapse and recurring AML patients. Alpha Biopharma has assembled an experienced management team with solid capabilities in pre-clinical development, pharmacology, medical sciences, clinical operations, and business development to advance its innovative treatment solutions to the market and improve life quality for cancer patients and commercialization. SOURCE ALPHA BIOPHARMA

Clinical StudyCell Therapy

25 Aug 2022

·www.prnewswire.com

Alpha Biopharma Announces Completion of its EVEREST Phase II/III Clinical Study of Zorifertinib in Non-Small Cell Lung Cancer Patients with Central Nervous System Metastases

SHANGHAI, Aug. 24, 2022 /PRNewswire/ -- Alpha Biopharma, a developer of innovative drugs, announces the completion of last patient last visit (LPLV) in its international, multicenter EVEREST phase II/III clinical study of Zorifertinib, a next-generation EGFR-TKI, in first line patients with advanced EGFRm+ non-small cell lung cancer (NSCLC) with central nervous system (CNS) metastases. Topline data from this MRCT study are expected around the end of 2022, at which time Alpha Biopharma could submit a New Drug Application (NDA) to the National Medical Products Administration (NMPA). As the international leading principal investigator (PI) of EVEREST study, Professor Yilong Wu, President of the Chinese Thoracic Oncology Group (CTONG), said: "EVEREST study is an international, multicenter, phase II/III randomized clinical study. It is also the only large-scale prospective international multicenter clinical study worldwide for first line EGFRm+ NSCLC patients with CNS metastases to date. It was carried out in 55 study sites located in Chinese mainland, Taiwan, South Korea, and Singapore, with a total enrollment of 492 patients. The clinical and preclinical data of Zorifertinib have shown its high blood-brain barrier (BBB) penetration, anti-tumor activity in metastatic CNS lesions, overall efficacy in both CNS and extra-cranial diseases, and similar safety profile as other EGFR-TKI drugs. If approved, it is expected to provide a valuable choice for treatment of EGFRm+ NSCLC patients with CNS metastases. As the name EVEREST suggests, the study sponsor and investigators are dedicated to solving important unmet clinical needs." Professor Jie Wang, Director of Oncology Department of Cancer Hospital Chinese Academy of Medical Sciences, and co-leading PI of EVEREST study, said: "Lung cancer with CNS metastases has always been a challenging problem and leading cause of death for these patients. Zorifertinib is a next-generation, high-potent EGFR-TKI drug targeting sensitive mutations of exon 19 deletion or L858R in EGFR gene with good exposure in CNS lesions. It is not a substrate of efflux transporter P-gp and BCRP, thus not only capable of fully passing through BBB, but also maintaining high drug exposure in the brain tissue and cerebrospinal fluid. It was intentionally designed to optimize its physicochemical and biochemical properties meet the requirements of CNS penetration, which has been proven to be the case in this and prior clinical studies. We look forward to the finale data readout and if positive, a direly needed treatment for these patients." Dr. Ruilin Song, Executive President of China Pharmaceutical Innovation and Research Development Association, said: "In the past three years, the COVID-19 pandemic in some regions of China has brought great challenges to innovative biotech companies. Many clinical study sites faced challenges in terms of regional lockdown, logistics, and clinical operations. However, the clinical development team at Alpha Biopharma and investigators worked together to overcome difficulties to achieve the key milestones of the EVEREST study. They diligently communicated with study sites to come up with solutions, paid full attention to the safety of the subjects and the quality of the trial data while ensuring the uninterrupted treatment of the subjects. In recognizing this pivotal milestone of EVEREST study completion, we would like to express sincere respect for the efforts of all relevant personnel involved in the study and wish Zorifertinib a smooth NDA submission. We are a step closer to bringing new hope to patients with CNS metastases of EGFRm+ NSCLC." About Zorifertinib Zorifertinib is a potent, oral, reversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR-TKI) activating mutation (L858R and Exon19Del). EGFR is widely expressed in human epidermal cells and stromal cells and is highly expressed in a variety of human malignancies, such as NSCLC. EGFR gene mutation will cause excessive epidermal growth factor receptors on the cell membrane surface, accelerate the abnormal growth and division of cells, and eventually lead to tumorigenesis. CNS metastases is common in EGFRm+ NSCLC patients and accompanied with poor prognosis of earlier disease progression, shorter survival, and lower quality of life. The BBB significantly increases the difficulty of drug penetration into CNS, which allows the CNS to be a refuge for lung cancer cells. Zorifertinib is a new-generation EGFR-TKI specifically designed to fully penetrate the BBB to target brain metastases. Zorifertinib is in late-stage clinical studies and has global intellectual property protection. About Alpha Biopharma Alpha Biopharma is a late-stage biopharmaceutical company focused on developing potential new therapies for cancer's unmet medical need. Founded in 2017, the Company has advanced its EGFRm+ targeted small molecule drug Zorifertinib to its Phase II/III trial (EVEREST) to treat NSCLC patients with brain metastases. In addition, Alpha Biopharma has initiated an IIT clinical study of an NK cell therapy targeting AML and is developing CAR-T cell therapy that it licensed from Wugen Inc. for the Greater China region. Alpha BioPharma's experienced team, leading clinicians, and collaborators integrate their oncology expertise to find innovative solutions to transform the lives of cancer patients. SOURCE ALPHA BIOPHARMA

Innovative DrugCell TherapySmall molecular drug

19 Jun 2018

·www.biospace.com

Chinese Biotechs Flex Financial Muscles With Continued Investments

Chinese companies and investors continue to flex their financial muscles with a series of deals this week that highlight the continued growing impact that country is having on the global pharmaceutical and biotech landscape. Chinese companies and investors continue to flex their financial muscles with a series of deals this week that highlight the continued growing impact that country is having on the global pharmaceutical and biotech landscape. This morning Shanghai-based Alpha Biopharma Inc. secured $65 million in Series A funding that will be used to support a multi-center Phase II study of AZD3759, AlphaBio’s lead product. AZD3759 is a next-generation small molecule tyrosine kinase inhibitor (TKI). It is specifically designed to treat epidermal growth factor receptor (EGFR) mutation positive non-small cell lung cancer (NSCLC) patients with central nervous system (CNS) metastases. In addition to advancing AZD3759, AlphaBio said the remaining proceeds from the Series A will be used to expand the company’s product pipeline. In its announcement, AlphaBio did not mention any particular acquisitions or licensing deals that could allow it to acquire a clinic-ready asset. Nor did the company mention taking any preclinical assets into the clinic. In Phase I testing, orally administered AZD3759 demonstrated efficient penetration into the brain and cerebrospinal fluid, which could be beneficial in creating anti-tumor effects in EGFR mutation positive NSCLC patients with CNS metastases. AlphaBio said many tyrosine kinase inhibitors are not effective in targeting NSCLC patients with CNS metastases due to their poor ability to penetrate the blood-brain barrier. Because of that inability, metastatic tumor cells in the central nervous system are left unchecked and continue to proliferate. AlphaBio’s Series A was supported by prominent Chinese venture capital firm Qiming Venture Partners, as well as TF Fund and the LYZZ Healthcare Venture Fund. China has seen consistently strong growth in its pharma and biotech industries. China had a 2017 pharmaceutical market valued at $122.6 billion, according to data from health-care information company IQVIA (formerly QuintilesIMS). IQVIA data shows China’s pharmaceutical market is expected to grow to between $145 billion and $175 billion by 2022. Not only is China seeing strong growth of its own biotech market, companies in China are also becoming strong investors in U.S. companies. This week Chinese investment firm Nan Fung Technology’s Pivotal Beta helped lead a $100 million investment round in Boston-based Stealth Biotherapeutics , a company developing treatments for mitochondrial dysfunction. The participation of Nan Fung Technology’s Pivotal Beta highlights the growing importance of Chinese money in the U.S. market. Reenie McCarthy, chief executive officer of Stealth, noted the importance of the foreign investment and how that can potentially lead to opening up a market in China. “We particularly welcome our new investors’ deep experience within the China healthcare market, which we view as an important frontier both for rare mitochondrial diseases under China’s recent rare disease initiative, as well as for diseases of aging,” McCarthy said in a statement. As a result of the investment, Chinese investor Vincent Cheung, the managing partner of Pivotal, will join the Stealth board of directors. Cheung said the Boston company’s mitochondrial therapeutic platform has the potential to “disrupt the current treatment paradigms for age-related indications. Last week Shanghai-based WuXi AppTec became the lead strategic investor in Insilico Medicine, a Baltimore biotech startup that has developed a drug discovery process for pharmaceutical companies using artificial intelligence and deep learning.

Phase 1Phase 2

100 Deals associated with Zorifertinib

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB14795

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
EGFR exon 19 Deletions Mutant Non-small Cell Lung Cancer	China	Alpha Biopharma (Jiangsu) Co., Ltd.	15 Nov 2024
EGFR exon 21 Substitution Mutant Non-small Cell Lung Cancer	China	Alpha Biopharma (Jiangsu) Co., Ltd.	15 Nov 2024

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
EGFR T790M Mutation Positive Non-Small Cell Lung Carcinoma	Phase 3	China	Alpha Biopharma (Jiangsu) Co., Ltd.	29 Oct 2018
EGFR T790M Mutation Positive Non-Small Cell Lung Carcinoma	Phase 3	Singapore	Alpha Biopharma (Jiangsu) Co., Ltd.	29 Oct 2018
EGFR T790M Mutation Positive Non-Small Cell Lung Carcinoma	Phase 3	South Korea	Alpha Biopharma (Jiangsu) Co., Ltd.	29 Oct 2018
EGFR T790M Mutation Positive Non-Small Cell Lung Carcinoma	Phase 3	Taiwan Province	Alpha Biopharma (Jiangsu) Co., Ltd.	29 Oct 2018
EGFR-mutated non-small Cell Lung Cancer	Phase 3	China	AstraZeneca Investment (China) Co. Ltd.	18 Oct 2018
EGFR-mutated non-small Cell Lung Cancer	Phase 3	Singapore	AstraZeneca Investment (China) Co. Ltd.	18 Oct 2018
EGFR-mutated non-small Cell Lung Cancer	Phase 3	South Korea	AstraZeneca Investment (China) Co. Ltd.	18 Oct 2018
EGFR-mutated non-small Cell Lung Cancer	Phase 3	Taiwan Province	AstraZeneca Investment (China) Co. Ltd.	18 Oct 2018
EGFR positive non-small cell lung cancer	Phase 2	China	AstraZeneca Investment (China) Co. Ltd.	19 Oct 2017
Advanced Lung Non-Small Cell Carcinoma	Phase 1	United States	AstraZeneca PLC	05 Nov 2014

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03653546 (EVEREST, Pubmed \| Med) Manual	Phase 3	EGFR-mutated non-small Cell Lung Cancer First line EGFR Mutation	439	Zorifertinib	pqnyihlgyz(tfyxvsfnvh): HR = 0.467 (95% CI, 0.352 - 0.619) View more	Positive	01 Oct 2024
				First-generation EGFR-TKI (gefitinib or erlotinib)
NCT03653546 (ASCO 12023 \| ASCO 22023) Manual	Phase 3	EGFR-mutated non-small Cell Lung Cancer First line EGFR Mutation	439	AZD3759 200 mg	rpmrtlfoat(yxzguywoss) = qskhrdkfpg jqmeqpvtwj (afpjqrvaqz, 8.2 - 9.7) View more	Superior	26 May 2023
				Gefitinib 250 mg or Erlotinib Hydrochloride 150 mg	rpmrtlfoat(yxzguywoss) = xmmdptansc jqmeqpvtwj (afpjqrvaqz, 6.3 - 8.0) View more
NCT03574402 (CTONG1702, ESMO_ELCC2023) Manual	Phase 2	EGFR-mutated non-small Cell Lung Cancer First line EGFR-mutant	30	AZD3759	mmurqyydrq(qofithfxwr) = pfcfhjesgl ryujlmenjy (gmfjmtpezs ) View more	Positive	31 Mar 2023
NCT02228369 (BLOOM, Pubmed \| Lancet Respir Med) Manual	Phase 1	EGFR-mutated non-small Cell Lung Cancer EGFR Mutation	67	AZD3759 (dose-escalation)	fdtzdnmern(yifljtbebp) = led to treatment discontinuation in one (4%) patient treated with 200 mg twice a day (grade 3 increase of alanine aminotransferase and aspartate aminotransferase) and two (13%) patients given 300 mg twice a day (grade 3 diarrhoea [n=1] and grade 3 skin rash [n=1]). fpsffzmsvw (addbzvqgjw ) View more	Positive	01 Nov 2017
				AZD3759 (dose-expansion)
NCT02228369 (BLOOM, ASCO2017)	Phase 1	Meningeal Leukemia \| EGFR-mutated non-small Cell Lung Cancer	38	AZD3759 200 mg BID	wbpxxktouz(oaqnfuroen) = 67% (12 out of 18) patients had drug-related dose interruption and/or reduction, however, there were no drug-related discontinuations xryjbarqcv (dplpbiufqc ) View more	Positive	30 May 2017
				AZD3759 300 mg BID
NCT02228369 (BLOOM, ASCO2017)	Phase 1	EGFR positive non-small cell lung cancer \| Advanced Lung Non-Small Cell Carcinoma	38	AZD3759 200 mg BID	evcdplfrby(vpamutygfa) = above pEGFR IC90 qrhhkbcgxc (jjskhxhytn ) View more	-	30 May 2017
				AZD3759 300 mg BID

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis